APO Research
Talk to an analyst

APO RESEARCH · REPORT

Infliximab Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Infliximab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025191 pages

Choose your research edition.

Industry ResearchInfliximab Injection Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Infliximab Injection Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Infliximab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infliximab Injection Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Infliximab Injection Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Infliximab Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Infliximab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Infliximab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Infliximab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Infliximab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Infliximab Injection include Yuxi Jiahe Biotechnology, Taizhou Maiboteike Pharmaceuticals, Hangzhou Bozhirui Biopharmaceuticals, Pfizer, Nippon Kayaku, Nichiiko, Janssen Biologics, Celltrion and Ayumi Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Infliximab Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Infliximab Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Infliximab Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Infliximab Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Infliximab Injection Segment by Company

Yuxi Jiahe Biotechnology

Taizhou Maiboteike Pharmaceuticals

Hangzhou Bozhirui Biopharmaceuticals

Pfizer

Nippon Kayaku

Nichiiko

Janssen Biologics

Celltrion

Ayumi Pharmaceuticals

AMGEN

Infliximab Injection Segment by Type

Original Drug

Generic Drug

Infliximab Injection Segment by Application

Hospital

Clinic

Other

Infliximab Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infliximab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infliximab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infliximab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Infliximab Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Infliximab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Infliximab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Infliximab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Infliximab Injection Industry Trends Table 2. Infliximab Injection Industry Drivers Table 3. Infliximab Injection Industry Opportunities and Challenges Table 4. Infliximab Injection Industry Restraints Table 5. Global Infliximab Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Infliximab Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Infliximab Injection Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Infliximab Injection Sales Market Share by Manufacturers Table 9. Global Infliximab Injection Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Infliximab Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Infliximab Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Infliximab Injection Manufacturers, Product Type & Application Table 13. Global Infliximab Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Infliximab Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Original Drug Table 17. Major Manufacturers of Generic Drug Table 18. Global Infliximab Injection Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Infliximab Injection Sales by Type (2021-2026) & (K Units) Table 20. Global Infliximab Injection Sales by Type (2027-2032) & (K Units) Table 21. Global Infliximab Injection Sales Market Share by Type (2021-2026) Table 22. Global Infliximab Injection Sales Market Share by Type (2027-2032) Table 23. Global Infliximab Injection Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Infliximab Injection Revenue by Type (2021-2026) & (K Units) Table 25. Global Infliximab Injection Revenue by Type (2027-2032) & (K Units) Table 26. Global Infliximab Injection Revenue Market Share by Type (2021-2026) Table 27. Global Infliximab Injection Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Other Table 31. Global Infliximab Injection Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Infliximab Injection Sales by Application (2021-2026) & (K Units) Table 33. Global Infliximab Injection Sales by Application (2027-2032) & (K Units) Table 34. Global Infliximab Injection Sales Market Share by Application (2021-2026) Table 35. Global Infliximab Injection Sales Market Share by Application (2027-2032) Table 36. Global Infliximab Injection Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Infliximab Injection Revenue by Application (2021-2026) & (K Units) Table 38. Global Infliximab Injection Revenue by Application (2027-2032) & (K Units) Table 39. Global Infliximab Injection Revenue Market Share by Application (2021-2026) Table 40. Global Infliximab Injection Revenue Market Share by Application (2027-2032) Table 41. Global Infliximab Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Infliximab Injection Sales by Region (2021-2026) & (K Units) Table 43. Global Infliximab Injection Sales Market Share by Region (2021-2026) Table 44. Global Infliximab Injection Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Infliximab Injection Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Infliximab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Infliximab Injection Sales by Country (2021-2026) & (K Units) Table 48. North America Infliximab Injection Sales by Country (2027-2032) & (K Units) Table 49. Europe Infliximab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Infliximab Injection Sales by Country (2021-2026) & (K Units) Table 51. Europe Infliximab Injection Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Infliximab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Infliximab Injection Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Infliximab Injection Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Infliximab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Infliximab Injection Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Infliximab Injection Sales by Country (2027-2032) & (K Units) Table 58. Global Infliximab Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Infliximab Injection Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Infliximab Injection Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Infliximab Injection Revenue Market Share by Region (2021-2026) Table 62. Global Infliximab Injection Revenue Market Share by Region (2027-2032) Table 63. Yuxi Jiahe Biotechnology Company Information Table 64. Yuxi Jiahe Biotechnology Business Overview Table 65. Yuxi Jiahe Biotechnology Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Yuxi Jiahe Biotechnology Infliximab Injection Product Portfolio Table 67. Yuxi Jiahe Biotechnology Recent Development Table 68. Taizhou Maiboteike Pharmaceuticals Company Information Table 69. Taizhou Maiboteike Pharmaceuticals Business Overview Table 70. Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Taizhou Maiboteike Pharmaceuticals Infliximab Injection Product Portfolio Table 72. Taizhou Maiboteike Pharmaceuticals Recent Development Table 73. Hangzhou Bozhirui Biopharmaceuticals Company Information Table 74. Hangzhou Bozhirui Biopharmaceuticals Business Overview Table 75. Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Product Portfolio Table 77. Hangzhou Bozhirui Biopharmaceuticals Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Pfizer Infliximab Injection Product Portfolio Table 82. Pfizer Recent Development Table 83. Nippon Kayaku Company Information Table 84. Nippon Kayaku Business Overview Table 85. Nippon Kayaku Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Nippon Kayaku Infliximab Injection Product Portfolio Table 87. Nippon Kayaku Recent Development Table 88. Nichiiko Company Information Table 89. Nichiiko Business Overview Table 90. Nichiiko Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Nichiiko Infliximab Injection Product Portfolio Table 92. Nichiiko Recent Development Table 93. Janssen Biologics Company Information Table 94. Janssen Biologics Business Overview Table 95. Janssen Biologics Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Janssen Biologics Infliximab Injection Product Portfolio Table 97. Janssen Biologics Recent Development Table 98. Celltrion Company Information Table 99. Celltrion Business Overview Table 100. Celltrion Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Celltrion Infliximab Injection Product Portfolio Table 102. Celltrion Recent Development Table 103. Ayumi Pharmaceuticals Company Information Table 104. Ayumi Pharmaceuticals Business Overview Table 105. Ayumi Pharmaceuticals Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Ayumi Pharmaceuticals Infliximab Injection Product Portfolio Table 107. Ayumi Pharmaceuticals Recent Development Table 108. AMGEN Company Information Table 109. AMGEN Business Overview Table 110. AMGEN Infliximab Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. AMGEN Infliximab Injection Product Portfolio Table 112. AMGEN Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Infliximab Injection Distributors List Table 116. Infliximab Injection Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Infliximab Injection Product Image Figure 2. Global Infliximab Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Infliximab Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Infliximab Injection Sales (2021-2032) & (K Units) Figure 5. Global Infliximab Injection Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Infliximab Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Original Drug Image Figure 9. Generic Drug Image Figure 10. Global Infliximab Injection Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Infliximab Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Infliximab Injection Sales Market Share by Type (2021-2032) Figure 13. Global Infliximab Injection Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Infliximab Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Infliximab Injection Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Other Image Figure 19. Global Infliximab Injection Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Infliximab Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Infliximab Injection Sales Market Share by Application (2021-2032) Figure 22. Global Infliximab Injection Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Infliximab Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Infliximab Injection Revenue Market Share by Application (2021-2032) Figure 25. North America Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Infliximab Injection Sales Market Share by Country (2021-2032) Figure 27. U.S. Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Infliximab Injection Sales Market Share by Country (2021-2032) Figure 32. Germany Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Infliximab Injection Sales Market Share by Country (2021-2032) Figure 39. China Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Infliximab Injection Sales Market Share by Country (2021-2032) Figure 47. Brazil Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Infliximab Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Infliximab Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Infliximab Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Infliximab Injection Revenue (2021-2032) & (US$ Million) Figure 58. North America Infliximab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Infliximab Injection Revenue (2021-2032) & (US$ Million) Figure 60. Europe Infliximab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Infliximab Injection Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Infliximab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Infliximab Injection Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Infliximab Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Infliximab Injection Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Infliximab Injection Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Original Drug
  • Generic Drug
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Yuxi Jiahe Biotechnology
  • Taizhou Maiboteike Pharmaceuticals
  • Hangzhou Bozhirui Biopharmaceuticals
  • Pfizer
  • Nippon Kayaku
  • Nichiiko
  • Janssen Biologics
  • Celltrion
  • Ayumi Pharmaceuticals
  • AMGEN

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Infliximab Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Infliximab Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Infliximab Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Infliximab Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Infliximab Injection Market Dynamics
  1. 2.1 Infliximab Injection Industry Trends
  2. 2.2 Infliximab Injection Industry Drivers
  3. 2.3 Infliximab Injection Industry Opportunities and Challenges
  4. 2.4 Infliximab Injection Industry Restraints
3 Infliximab Injection Market by Manufacturers
  1. 3.1 Global Infliximab Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Infliximab Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global Infliximab Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Infliximab Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Infliximab Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Infliximab Injection Manufacturers, Product Type & Application
  7. 3.7 Global Infliximab Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Infliximab Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Infliximab Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Infliximab Injection Tier 1, Tier 2, and Tier 3
4 Infliximab Injection Market by Type
  1. 4.1 Infliximab Injection Type Introduction
  2. 4.1.1 Original Drug
  3. 4.1.2 Generic Drug
  4. 4.2 Global Infliximab Injection Sales by Type
  5. 4.2.1 Global Infliximab Injection Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Infliximab Injection Sales by Type (2021-2032)
  7. 4.2.3 Global Infliximab Injection Sales Market Share by Type (2021-2032)
  8. 4.3 Global Infliximab Injection Revenue by Type
  9. 4.3.1 Global Infliximab Injection Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Infliximab Injection Revenue by Type (2021-2032)
  11. 4.3.3 Global Infliximab Injection Revenue Market Share by Type (2021-2032)
5 Infliximab Injection Market by Application
  1. 5.1 Infliximab Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Infliximab Injection Sales by Application
  6. 5.2.1 Global Infliximab Injection Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Infliximab Injection Sales by Application (2021-2032)
  8. 5.2.3 Global Infliximab Injection Sales Market Share by Application (2021-2032)
  9. 5.3 Global Infliximab Injection Revenue by Application
  10. 5.3.1 Global Infliximab Injection Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Infliximab Injection Revenue by Application (2021-2032)
  12. 5.3.3 Global Infliximab Injection Revenue Market Share by Application (2021-2032)
6 Global Infliximab Injection Sales by Region
  1. 6.1 Global Infliximab Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Infliximab Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Infliximab Injection Sales by Region (2021-2026)
  4. 6.2.2 Global Infliximab Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Infliximab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Infliximab Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Infliximab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Infliximab Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Infliximab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Infliximab Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Infliximab Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Infliximab Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Infliximab Injection Revenue by Region
  1. 7.1 Global Infliximab Injection Revenue by Region
  2. 7.1.1 Global Infliximab Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Infliximab Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global Infliximab Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global Infliximab Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Infliximab Injection Revenue (2021-2032)
  8. 7.2.2 North America Infliximab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Infliximab Injection Revenue (2021-2032)
  11. 7.3.2 Europe Infliximab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Infliximab Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Infliximab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Infliximab Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Infliximab Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Yuxi Jiahe Biotechnology
  2. 8.1.1 Yuxi Jiahe Biotechnology Company Information
  3. 8.1.2 Yuxi Jiahe Biotechnology Business Overview
  4. 8.1.3 Yuxi Jiahe Biotechnology Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yuxi Jiahe Biotechnology Infliximab Injection Product Portfolio
  6. 8.1.5 Yuxi Jiahe Biotechnology Recent Developments
  7. 8.2 Taizhou Maiboteike Pharmaceuticals
  8. 8.2.1 Taizhou Maiboteike Pharmaceuticals Company Information
  9. 8.2.2 Taizhou Maiboteike Pharmaceuticals Business Overview
  10. 8.2.3 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Taizhou Maiboteike Pharmaceuticals Infliximab Injection Product Portfolio
  12. 8.2.5 Taizhou Maiboteike Pharmaceuticals Recent Developments
  13. 8.3 Hangzhou Bozhirui Biopharmaceuticals
  14. 8.3.1 Hangzhou Bozhirui Biopharmaceuticals Company Information
  15. 8.3.2 Hangzhou Bozhirui Biopharmaceuticals Business Overview
  16. 8.3.3 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hangzhou Bozhirui Biopharmaceuticals Infliximab Injection Product Portfolio
  18. 8.3.5 Hangzhou Bozhirui Biopharmaceuticals Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Infliximab Injection Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Nippon Kayaku
  26. 8.5.1 Nippon Kayaku Company Information
  27. 8.5.2 Nippon Kayaku Business Overview
  28. 8.5.3 Nippon Kayaku Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Nippon Kayaku Infliximab Injection Product Portfolio
  30. 8.5.5 Nippon Kayaku Recent Developments
  31. 8.6 Nichiiko
  32. 8.6.1 Nichiiko Company Information
  33. 8.6.2 Nichiiko Business Overview
  34. 8.6.3 Nichiiko Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Nichiiko Infliximab Injection Product Portfolio
  36. 8.6.5 Nichiiko Recent Developments
  37. 8.7 Janssen Biologics
  38. 8.7.1 Janssen Biologics Company Information
  39. 8.7.2 Janssen Biologics Business Overview
  40. 8.7.3 Janssen Biologics Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Janssen Biologics Infliximab Injection Product Portfolio
  42. 8.7.5 Janssen Biologics Recent Developments
  43. 8.8 Celltrion
  44. 8.8.1 Celltrion Company Information
  45. 8.8.2 Celltrion Business Overview
  46. 8.8.3 Celltrion Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Celltrion Infliximab Injection Product Portfolio
  48. 8.8.5 Celltrion Recent Developments
  49. 8.9 Ayumi Pharmaceuticals
  50. 8.9.1 Ayumi Pharmaceuticals Company Information
  51. 8.9.2 Ayumi Pharmaceuticals Business Overview
  52. 8.9.3 Ayumi Pharmaceuticals Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ayumi Pharmaceuticals Infliximab Injection Product Portfolio
  54. 8.9.5 Ayumi Pharmaceuticals Recent Developments
  55. 8.10 AMGEN
  56. 8.10.1 AMGEN Company Information
  57. 8.10.2 AMGEN Business Overview
  58. 8.10.3 AMGEN Infliximab Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AMGEN Infliximab Injection Product Portfolio
  60. 8.10.5 AMGEN Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Infliximab Injection Value Chain Analysis
  2. 9.1.1 Infliximab Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Infliximab Injection Production Mode & Process
  6. 9.2 Infliximab Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Infliximab Injection Distributors
  9. 9.2.3 Infliximab Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst